Pluristem reports success in stem cell heart attack treatment

Pluristem Therapeutics Ltd. (Nasdaq:PSTI; DAX: PJT: PLTR) today announced that its PLacental eXpanded (PLX) cells improve several parameters in acute myocardial infarction (heart attacks) in animals. The preclinical trial was conducted at the Center for Regenerative Therapies in Germany.

The trial included 20 mice, which were given induced heart attacks. Half the mice were then given either PLX cells, and the other half were given a cell-free medium as a control. Five other mice underwent a sham (placebo) operation. After four weeks, the mice underwent an ECG, and were then killed for a physical examination of their hearts. The mice which received PLX had improved cardiac muscle function compared with the control group.

Study leader Prof. Christof Stamm said, "As a cardiac surgeon, the unique ability demonstrated by Pluristem's PLX cells for the treatment of heart disease is very exciting." He added, "PLX cells showed promising results in the AMI studies."

Pluristem chairman and CEO Zami Aberman said, "These results demonstrate the potential benefits of our cells for use in the treatment of ischemic heart disease, a multi-billion dollar annual market, and one in which many pharmaceutical companies are constantly looking to provide patients with innovative and effective solutions. In addition to moving ahead with our AMI trial, we look forward to continuing to work on finding cell therapy solutions for numerous debilitating diseases."

An article in the New England Journal of Medicine states that 624,000 patients suffer an acute myocardial infarction annually in the US, a number that will most likely increase with the rising prevalence of obesity, diabetes and the aging of the population.

Pluristem's share price rose 5.1% by mid-afternoon on the TASE today to NIS 8.50, after closing at $2.15 on Nasdaq yesterday, giving a market cap of $95 million. The share is up 6.5% in premarket trading on Nasdaq today.

Published by Globes [online], Israel business news - http://www.globes-online.com - on March 20, 2012

Copyright of Globes Publisher Itonut (1983) Ltd. 2012

Excerpt from:
Pluristem reports success in stem cell heart attack treatment

2nd Lee Co. doctor's license restricted in stem cell case

2nd Lee Co. doctor's license restricted in stem cell case

FORT MYERS, Fla.- Another Lee County doctor is caught in the center of a stem cell controversy. The State Department of Health has issued an emergency license restriction to Dr. Konstantine Yankopolus, a general practitioner.

Dr. Yankopolus is still allowed to practice general medicine and is treating patients. The license restriction mandates he can't do anything involving stem cell treatment.

It's business as usual at his office on Colonial Blvd.

The doctor is still treating patients, but an emergency order issued from the Florida Department of Health, Monday prevents him from doing anything with stem cells.

The order says Dr. Yankopolus' license "is hereby immediately restricted from providing, collaborating, facilitating, procuring, referring or advising on any stem cell treatment."

The action comes after the state suspended the license of his colleague, Dr. Zannos Grekos' earlier this month.

The emergency order says Dr. Yankopolus helped Dr. Grekos perform stem cell therapy on the late Richard Polling despite knowing the Bonita Springs cardiologist was not allowed to do such a procedure.

The state Surgeon General alleges, Dr. Yankopolus falsified Polling's records.

He writes, "Subsequent to the death of patient R.P., Dr. Yankopolus entered a false medical progress note in R.P.'s chart falsely indicating that no stem cell preparation was infused."

Read the original:
2nd Lee Co. doctor's license restricted in stem cell case

Second doctor's license restricted after patient's death

LEE COUNTY, FL -

A Fort Myers doctor's license has been restricted for allegedly assisting Dr. Zannos Grekos in a stem cell procedure on a patient who died. Dr. Konstantine Yankopolus is restricted from performing or assisting in any stem cell procedures.

The Emergency Restriction Order alleges Yankopolus knew that Grekos' was restricted from providing any stem cell treatment, yet agreed to assist Grekos in performing a stem cell treatment.

The patient who received the alleged stem cell treatment went into cardiac arrest during the procedure at Grekos' office, then died later at the hospital.

Yankopolus is also accused of entering a false medical progress note in the patient's chart falsely indicating no stem cell preparation was infused, the ERO states.

Yankopolus prepared an addendum on March 11 that indicates the stem cell preparation was infused leading to the patient's cardiac arrest and death, according to the ERO.

Dr. Yankopolus says he would do the procedure again if he had the chance.

"He was at the tail-end of his life. We offered him an option to extend that," Dr. Yankopolus said. "We have dealt with such people in the past, and they've done well."

Yankopolus admits he knew Dr. Grekos was prohibited from performing stem cell treatments.

"I acted in good faith as a humanitarian to save this man's life. If they want to pull it for that, they may do so," Yankopolus said.

Go here to see the original:
Second doctor's license restricted after patient's death

Stem Cell Therapy Could Boost Kidney Transplant Success: Study

TUESDAY, March 20 (HealthDay News) -- A novel technique that uses a kidney transplant recipient's own stem cells may someday replace or reduce the initial use of anti-rejection medications, new research suggests.

Six months after receiving a kidney transplant, only about 8 percent of people given their own mesenchymal stem cells experienced rejection compared with almost 22 percent of people on the standard anti-rejection drugs, according to the study.

"Mesenchymal stem cells are stem cells that can be differentiated into a variety of cells," explained Dr. Camillo Ricordi, study senior author and director of the Cell Transplant Center and Diabetes Research Institute at the University of Miami Miller School of Medicine.

"If you infuse mesenchymal stem cells at the time of the transplant, you could replace the use of powerful anti-rejection drugs, and maybe replace immunosuppressants altogether," he said. This technique could be used in the transplantation of islet cells (in the pancreas) for people with type 1 diabetes, and for other organ transplants, such as the liver, he added.

The people given their own stem cells also had improved kidney function earlier after transplant, Ricordi said.

Results of the study appear in the March 21 issue of the Journal of the American Medical Association.

One of the biggest remaining hurdles in organ transplantation remains the need for powerful anti-rejection and immune-suppressing medications after the transplant.

"Basically, the way we prevent kidney rejections is by putting you on very powerful anti-rejection drugs and immunosuppressive agents to prevent your cells from attacking the foreign organ," said Dr. Robert Provenzano, chair of the department of nephrology, hypertension and transplantation at St. John Providence Health System in Detroit. "But, the current standard has some problems, like an increased risk of infections and the possibility of creating a cancer."

The body's immune system sends out surveillance cells to protect the body against foreign invaders, such as a bacteria, virus or, in this case, a new organ, Provenzano said. The current method of preventing these cells from attacking the new organ is essentially to destroy the surveillance cells. But mesenchymal cells can naturally suppress those surveillance cells so they don't attack, he said.

To see if this suppression would be enough to prevent rejection, Ricordi and his colleagues, including researchers from Xiamen University in China, recruited 159 people with serious kidney disease who were on dialysis. They ranged in age from 18 to 61.

Original post:
Stem Cell Therapy Could Boost Kidney Transplant Success: Study

Cryo-Save Group N.V.: Revenue up 4% to EUR41.9 million

Cryo-Save Group N.V. (Euronext: CRYO, Cryo-Save, or the Group), the leading international stem cell storage brand and the largest family stem cell bank in Europe, has published its financial results for the year ended 31 December 2011.

Financial highlights

Revenue up 4% to EUR41.9 million (2010: EUR40.4 million) Operating expenses before depreciation and amortisation increased with EUR1.6 million mainly due to further investments in Cryo-Lip() (EUR0.8 million) and acquisition impact (EUR0.7 million) EBITDA(*): EUR6.3 million (2010: EUR7.3 million) EBITA(**): EUR4.5 million (2010: EUR5.8 million) Operating profit: EUR2.9 million (2010: EUR4.5 million) Profit before taxation: EUR3.0 million (2010: EUR3.9 million) Net profit: EUR2.3 million (2010: EUR2.6 million) Basic earnings per share 25.0 euro cents (2010: 27.6 euro cents) Robust net cash from operating activities EUR6.2 million (2010: EUR 2.8 million) Solid cash position of EUR7.0 million as at 31 December 2011 (2010: EUR6.0 million) Dividend per share of EUR0.08, up 14% (2010: EUR0.07) () (*) EBITDA is defined as Earnings Before Interest, Taxation Depreciation and Amortisation (**) EBITA is defined as Earnings Before Interest, Taxation and Amortisation of identified intangible assets

Operational highlights

39,900 new samples stored in 2011, up 4% compared to previous year (2010: 38,300). Of these, 25,200 were new cord blood samples and 14,700 new cord tissue samples 204,000 samples have been stored in total at 31 December 2011 67% of new customers opt for combined service of cord blood and cord tissue storage Acquisition of Serbian distributor Life R.F. for EUR2.3 million in cash and 30,000 Cryo-Save shares Cryo-Save USA founded, to commercialize and develop the Cryo-Lip() service in North America Cryo-Save South Africa joint venture established and stem cell processing and storage laboratory opened in Cape Town together with John Daniel Holdings and Lazaron Biotechnologies A six-year-old girl from Portugal with Cerebral Palsy was treated at Duke University in the US with her own cord blood stem cells, which were stored and released by Cryo-Save

Outlook

* Cryo-Save has a strong strategic position and product portfolio to further enhance its business * Cryo-Save will continue to collaborate with new partners and make acquisitions in line with its strategy to grow in current markets as well as in new geographies * Promising developments continue in the use of stem cell technology in the treatment of diseases. Thus enhancing the added value of Cryo-Saves high- tech storage solutions of stem cells * Fast growing fields of cellular therapy and regenerative medicine offer further attractive market potential for Cryo-Save * The Group is confident it will continue to maintain its market leading position as the leading international stem cell storage brand and the largest family stem cell bank in Europe

Revenue increased with EUR1.4 million to EUR41.9 million, largely due to increased sales volumes in several countries, acquisitions and increased number of new cord tissue samples, partly offset by lower business volume in mainly Southern Europe. The impact of the economic crisis also resulted in a significantly lower number of births in almost all countries. An increasing demand for discounts on the service fee and instalment plans to facilitate the payment of the service fee has been another factor affecting revenue growth.

The gross profit margin decreased with 1% to 66.6%, among others due to an increased demand for higher reimbursements of the collection of the umbilical cord blood and cord tissue in the hospitals. The gross profit margin remained at the same level compared to the second half of 2010 (66.5%).

Operational expenses increased with EUR1.6 million due to incremental expenses related to Cryo-Lip() (EUR0.8 million), and the impact of the acquisitions of Tissue Bank Cryo Center Bulgaria AD ("TBCCB") and Life R.F. doo, Serbia ("Life") (EUR0.7 million).

Go here to see the original:
Cryo-Save Group N.V.: Revenue up 4% to EUR41.9 million

Cryo-Save Group N.V.: Revenue up 4% to €41.9 million

Cryo-Save Group N.V. (Euronext: CRYO, `Cryo-Save`, or `the Group`), the leading international stem cell storage brand and the largest family stem cell bank in Europe, has published its financial results for the year ended 31 December 2011.

Financial highlights

Revenue up 4% to 41.9 million (2010: 40.4 million) Operating expenses before depreciation and amortisation increased with 1.6 million mainly due to further investments in Cryo-Lip (0.8 million) and acquisition impact (0.7 million) EBITDA*: 6.3 million (2010: 7.3 million) EBITA**: 4.5 million (2010: 5.8 million) Operating profit: 2.9 million (2010: 4.5 million) Profit before taxation: 3.0 million (2010: 3.9 million) Net profit: 2.3 million (2010: 2.6 million) Basic earnings per share 25.0 euro cents (2010: 27.6 euro cents) Robust net cash from operating activities 6.2 million (2010: 2.8 million) Solid cash position of 7.0 million as at 31 December 2011 (2010: 6.0 million) Dividend per share of 0.08, up 14% (2010: 0.07)

* EBITDA is defined as Earnings Before Interest, Taxation Depreciation and Amortisation ** EBITA is defined as Earnings Before Interest, Taxation and Amortisation of identified intangible assets

Operational highlights

39,900 new samples stored in 2011, up 4% compared to previous year (2010: 38,300). Of these, 25,200 were new cord blood samples and 14,700 new cord tissue samples 204,000 samples have been stored in total at 31 December 2011 67% of new customers opt for combined service of cord blood and cord tissue storage Acquisition of Serbian distributor Life R.F. for 2.3 million in cash and 30,000 Cryo-Save shares Cryo-Save USA founded, to commercialize and develop the Cryo-Lip service in North America Cryo-Save South Africa joint venture established and stem cell processing and storage laboratory opened in Cape Town together with John Daniel Holdings and Lazaron Biotechnologies A six-year-old girl from Portugal with Cerebral Palsy was treated at Duke University in the US with her own cord blood stem cells, which were stored and released by Cryo-Save

Outlook

Revenue increased with 1.4 million to 41.9 million, largely due to increased sales volumes in several countries, acquisitions and increased number of new cord tissue samples, partly offset by lower business volume in mainly Southern Europe. The impact of the economic crisis also resulted in a significantly lower number of births in almost all countries. An increasing demand for discounts on the service fee and instalment plans to facilitate the payment of the service fee has been another factor affecting revenue growth.

The gross profit margin decreased with 1% to 66.6%, among others due to an increased demand for higher reimbursements of the collection of the umbilical cord blood and cord tissue in the hospitals. The gross profit margin remained at the same level compared to the second half of 2010 (66.5%).

Operational expenses increased with 1.6 million due to incremental expenses related to Cryo-Lip (0.8 million), and the impact of the acquisitions of Tissue Bank Cryo Center Bulgaria AD ("TBCCB") and Life R.F. doo, Serbia ("Life") (0.7 million).

Excerpt from:
Cryo-Save Group N.V.: Revenue up 4% to €41.9 million

Hero Dog Receives Stem Cell Therapy

Stem Cell Therapy Helping Heroic Dogs Recover

News4's Darcy Spencer explains how a breakthrough treatment is helping search and rescue dogs like Red recover after years of working in disaster zones.

A breakthrough treatment is helping area search-and-rescue dogs that played key roles on Sept. 11, 2001, and during other disasters.

Red's first assignment as a search, rescue and recovery dog was at the Pentagon following the 9/11 attacks. Years of rescue work and a 12-foot fall from a ladder have taken a toll. Arthritis forced Red into retirement in July and turned her into a couch potato.

The 12-year-old black lab received a breakthrough stem cell treatment today that will ease her pain and give her more mobility.

Her veterinarian, Dr. John Herrity, of the Burke Animal Clinic, has done more than two dozen of the stem cell operations developed by Medivet America, which also donated the cost of the procedure.

The treatment won't bring Red back out of retirement, but it is expected to put spring back in her step within a couple of months.

Two other 9/11 search-and-rescued dogs have been treated with stem cell therapy and are back to their normal activities.

Link:
Hero Dog Receives Stem Cell Therapy

9/11 Search And Rescue Dog Gets Stem Cell Treatment

BURKE, Va. (WUSA) -- Red, a black lab from Annapolis, has spent the last ten years as a search and rescue dog. Her missions have included Hurricane Katrina, the La Plata tornadoes, and the Pentagon after 9/11.

"The search and rescue dogs at the Pentagon are credited with finding 70% of the human remains," said Heather Roche, Red's owner and handler. "That helped a whole lot of those families actually get closure."

At just under two years old, 9/11 was Red's first search. Today, she's one of the last 9/11 search and rescue dogs still alive. She retired last July due to severe arthritis.

"The last few months, she would like to be a couch potato but she can't even get on the couch any more," said Roche. "It would be nice if she could do those kinds of things that she misses."

Roche brought Red to the Burke Animal Clinic for stem cell regenerative therapy compliments of MediVet America, the company that developed the in-clinic stem cell technology.

"This is a small something that we can give back as a way of saying thanks for what you guys have done for us," said Dr. John Herrity at the Burke Animal Clinic. "We are just taking fat from Red's side and then we are going to spin it down, process it, extract the stem cells from there."

Red received her first injection just a few hours after she woke up from surgery. The rest of her extracted stem cells will be stored free of charge for use in follow-up treatments.

"We've done about 28 dogs and of those dogs we've had about 75-80% of them doing very well," said Dr. Herrity.

Two other 9/11 dogs that recently received the same stem cell therapy are able to run, climb, and play again. Dr. Herrity's own dog, Bradley, is living proof that the treatment works. Bradley received the same stem cell treatment about one year ago and he's made great progress.

"Hopefully in about 2-3 months, she will be more comfortable, moving around, wanting to play more," said Dr. Herrity.

Read the rest here:
9/11 Search And Rescue Dog Gets Stem Cell Treatment

State: Second doctor's license restricted for performing stem cell treatment on patient who died

Dr. Konstantine K. Yankopolus

The state Department of Health restricted a second doctor's license for working under the direction of Dr. Zannos Grekos in performing a stem cell treatment and for falsifying a medical report after a patient died, according to the state order.

The emergency license restriction is against Dr. Konstantine K. Yankopolus, 3880 Colonial Blvd., Suite 2, Fort Myers, according to the order issued by the state health department late Monday.

The restriction only prohibits Yankopolus from doing anything with stem cells. After a career as an obstetrician/gynecologist, he is now in general practice.

"We attempted a life-saving procedure on a very sick patient and it didn't go well," Yankopolus said Monday night. "Our motivation was pure the patient had no other option."

The state's action comes on the heels of Grekos attorney last week issuing a statement that another doctor, and not his client, was involved in the treatment of a 77-year-old Indiana man who died March 2. Grekos attorney also denied that a stem cell treatment was performed, only liposuction.

The state health department suspended Grekos license after the death, saying Grekos violated an earlier restriction that he not to do anything with stem cells or bone marrow aspirate in his practice at 9500 Bonita Beach Road, Suite 310.

Lee County sheriff's authorities identified the man as Richard Poling, of Newburgh, Ind. The Sheriff's Office also is conducting a criminal probe.

Grekos has been under state scrutiny by state health regulators for well over a year when an earlier patient, a 66-year-old breast cancer patient, went to him for stem cell treatment in 2010 for neurological problems. She later fell, suffered severe brain damage and was taken off life support. After her death, the state ordered Grekos not to do anything with stem cells or bone marrow aspirate in his practice.

The restriction did not prohibit him from conducting educational seminars in the community about stem cell therapy or from arranging for patients to go for the treatment in the Dominican Republic.

More here:
State: Second doctor's license restricted for performing stem cell treatment on patient who died

Huntington's Disease – Stem Cell Therapy Potential

Editor's Choice Academic Journal Main Category: Huntingtons Disease Also Included In: Stem Cell Research Article Date: 19 Mar 2012 - 10:00 PDT

email to a friend printer friendly opinions

Current Article Ratings:

However, according to a study published March 15 in the journal Cell Stem Cell, a special type of brain cell created from stem cells could help restore the muscle coordination deficits that are responsible for uncontrollable spasms, a characteristic of the disease. The researchers demonstrated that movement in mice with a Huntington's-like condition could be restored.

Su-Chun Zhang, a University of Wisconsin-Madison neuroscientist and the senior author of the study, said:

In the study Zhang, who is an expert in creating various types of brain cells from human embryonic or induce pluripotent stem cells, and his team focused on GABA neurons. The degradation of GABA cells causes the breakdown of a vital neural circuit and loss of motor function in individuals suffering from Huntington's disease.

According to Zhang, GABA neurons generate a vital neurotransmitter, a chemical that helps support the communication network in the brain that coordinates movement.

Zhang and his team at the UW-Madison Waisman Center, discovered how to generate large quantities of GABA neurons from human embryonic stem cells. The team's goal was to determine whether these cells would safely integrate into the brain of a mouse model of Huntington's disease.

The researchers discovered that not only did the cells integrate, they were projected to the right target and were able to effectively restore the damaged communication network and restore motor function.

Zhang says that the results were astonishing, as GABA neurons reside in the basal ganglia, a part of the brain which plays a vital role in voluntary motor coordination. However, the GABA neurons exert their influence at a distance on cells in the midbrain via the circuit powered by the GABA neuron chemical neurotransmitter.

Follow this link:
Huntington's Disease - Stem Cell Therapy Potential